Squadron Capital Llc Sells 16,300 Shares of OrthoPediatrics (NASDAQ:KIDS) Stock

OrthoPediatrics Corp. (NASDAQ:KIDS) major shareholder Squadron Capital Llc sold 16,300 shares of the firm’s stock in a transaction on Tuesday, August 25th. The stock was sold at an average price of $24.74, for a total value of $403,262.00. Following the completion of the sale, the insider directly owned 6,881,464 shares of the company’s stock, valued at $170,247,419.36. The trade was a 0.24% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Major shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

Squadron Capital Llc also recently made the following trade(s):

• On Wednesday, August 26th, Squadron Capital Llc sold 18,000 shares of OrthoPediatrics stock. The shares were sold at an average price of $24.28, for a total transaction of $437,040.00.
• On Monday, August 24th, Squadron Capital Llc sold 4,000 shares of OrthoPediatrics stock. The stock was sold at an average price of $25.75, for a total transaction of $103,000.00.

OrthoPediatrics Stock Performance

KIDS traded down $0.47 on Wednesday, reaching $24.03. 169,608 shares of the stock were exchanged, compared to its average volume of 171,545. OrthoPediatrics Corp. has a fifty-two week low of $14.42 and a fifty-two week high of $26.74. The firm has a market capitalization of $627.42 million, a PE ratio of -14.30 and a beta of 0.98. The company has a debt-to-equity ratio of 0.28, a current ratio of 4.78 and a quick ratio of 2.17. The company’s 50-day moving average price is $21.11 and its 200 day moving average price is $18.53.

OrthoPediatrics (NASDAQ:KIDS) last issued its earnings results on Tuesday, August 4th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.30) by $0.04. The firm had revenue of $70.51 million during the quarter, compared to analysts’ expectations of $68.21 million. OrthoPediatrics had a negative net margin of 15.72% and a negative return on equity of 8.10%. As a group, sell-side analysts forecast that OrthoPediatrics Corp. will post -1.14 EPS for the current fiscal year.

Hedge Funds Weigh In On OrthoPediatrics

A number of hedge funds have recently bought and sold shares of the business. Millennium Management LLC grew its holdings in OrthoPediatrics by 48.0% in the fourth quarter. Millennium Management LLC now owns 1,396,495 shares of the company’s stock valued at $24,802,000 after purchasing an additional 452,840 shares during the period. BlackRock Inc. acquired a new position in shares of OrthoPediatrics during the 2nd quarter worth approximately $24,347,000. Vanguard Group Inc. lifted its position in shares of OrthoPediatrics by 1.1% during the 3rd quarter. Vanguard Group Inc. now owns 961,330 shares of the company’s stock valued at $17,813,000 after buying an additional 10,927 shares in the last quarter. Granahan Investment Management LLC lifted its position in shares of OrthoPediatrics by 35.1% during the 1st quarter. Granahan Investment Management LLC now owns 896,741 shares of the company’s stock valued at $14,231,000 after buying an additional 232,760 shares in the last quarter. Finally, Wasatch Advisors LP grew its stake in OrthoPediatrics by 56.6% in the 2nd quarter. Wasatch Advisors LP now owns 515,677 shares of the company’s stock valued at $9,865,000 after acquiring an additional 186,357 shares during the period. Hedge funds and other institutional investors own 69.05% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have issued reports on KIDS. Truist Financial set a $22.00 price target on OrthoPediatrics in a report on Wednesday, August 5th. TD Cowen reaffirmed a “buy” rating on shares of OrthoPediatrics in a report on Monday, June 15th. Needham & Company LLC boosted their target price on shares of OrthoPediatrics from $30.00 to $35.00 and gave the company a “buy” rating in a research note on Wednesday, August 5th. BTIG Research increased their price target on shares of OrthoPediatrics from $24.00 to $29.00 and gave the stock a “buy” rating in a report on Thursday, August 20th. Finally, Piper Sandler restated an “overweight” rating and set a $25.00 price target (up from $22.00) on shares of OrthoPediatrics in a research report on Wednesday, August 5th. Nine research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $26.44.

OrthoPediatrics Company Profile

OrthoPediatrics Corp., founded in 2007 and headquartered in Warsaw, Indiana, is a medical device company dedicated exclusively to providing orthopedic solutions for children. The company focuses on developing, manufacturing and marketing a broad portfolio of implants and instruments designed to address a wide range of pediatric conditions, including trauma, deformity correction, spine disorders and sports injuries.

The company’s product lines include locking plates and screws for upper and lower extremity reconstruction, intramedullary nails for femur and tibia stabilization, and specialized systems such as the MAGEC Magnetic Growth Rod for treatment of early-onset scoliosis.